The Biomarker Analysis in Locally Advanced Cervical Cancer

Status Active, not recruiting

Clinical Trial Summary

Sonic hedgehog (Shh) signaling, including Gli1, is critical to treatment resistance. For optimizing cervical cancer treatment, the pathological prognostic factors determine whether to administer adjuvant therapy. However, the majority of clinical results was from squamous cell carcinoma, rendering conclusions for adenocarcinoma less convincing. We aimed to examine the role of Shh signaling in long-term clinical outcomes of cervical adenocarcinoma after receiving major surgery.

Clinical Trial Description

Surgery, radiotherapy, and chemotherapy could achieve favorable locoregional control in cervical cancer. Although good local control results, distant failure plays a major role in patients with treatment failure.

We were interested in the potential biomarkers for recurrence after primary treatment for the following reasons. We wanted to identify patients at a high risk of recurrence. Such patients must be intensively monitored. We required baseline data, such as the actuarial relapse rate, for evaluation in an additional randomized study. Hence, we retrospectively analyzed the potential biomarkers for recurrence in cervical cancer. Statistical analysis of the data was done using the chi-square test. Disease free survival curves were constructed using the Kaplan-Meier method. Comparisons between curves were performed using the log-rank test. Multivariate analyses of factors associated with local and distant failure were made by logistic regression analysis.

From 1987 to 2002, 62 patients with cervical adenocarcinoma that received major surgery were enrolled for analysis of Shh signaling with a median follow-up period for 172.6 months (IQR 33.0-226.2 months). External beam radiotherapy with 50-60 Gy followed by brachytherapy with 30 Gy was delivered with or without concurrent weekly cisplatin 40 mg/m2. Clinical outcomes in terms of local recurrence, progression free survival (PFS) and overall survival (OS) will be analyzed. The expressions of Shh, Ptch-1, Smo and Gli1 were assessed by immunohistochemistry. Statistics will be performed using International Business Machines (IBM) Statistical Package for the Social Science (SPSS) v22. ;

Study Design

Related Conditions & MeSH terms

Uterine Cervical Neoplasms

Clinical Trial Details

NCT number	NCT03635216
Study type	Observational
Source	Mackay Memorial Hospital
Contact
Status	Active, not recruiting
Phase
Start date	May 21, 2018
Completion date	May 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03225443` - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy	N/A
Recruiting	`NCT01373723` - Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer	N/A
Terminated	`NCT01234480` - Intended Use Study of the BD SurePath Plus™ Pap
Completed	`NCT02808832` - An HPV Vaccine Provider Intervention in Safety Net Clinics	N/A
Terminated	`NCT01194609` - A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer	Phase 1/Phase 2
Terminated	`NCT01075412` - FLT PET Imaging for Cervical Cancer	Phase 2
Completed	`NCT01014026` - Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention	Phase 3
Completed	`NCT02865889` - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications	N/A
Completed	`NCT00377845` - Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.	Phase 0
Recruiting	`NCT05531981` - Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
Recruiting	`NCT05393440` - First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer	Phase 1
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Completed	`NCT02866006` - Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer	Phase 1/Phase 2
Completed	`NCT02320578` - 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial	N/A
Completed	`NCT03270995` - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study	N/A
Terminated	`NCT02900248` - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Not yet recruiting	`NCT05065853` - Urinary and Vaginal HPV Testing in Cervical Cancer Screening
Completed	`NCT01231945` - Low-Cost Molecular Cervical Cancer Screening Study	N/A
Completed	`NCT01717391` - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers	Phase 2
Active, not recruiting	`NCT04947605` - Epidemiological Landscape of Cervical Cancer in Latin America

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.